Sector |
|
Compare with Sector peers |
Industry |
|
Compare with Industry peers |
Website | http://www.eris.co.in | |
Market Cap | 7,784.20 Cr. | |
Enterprise Value(EV) | 7,930.13 Cr. | 2022-09 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | 29.20 | Trailing Twelve Months Ending 2022-12 |
Price-Earning Ratio (PE) | 19.56 | Trailing Twelve Months Ending 2022-12 |
Industry PE | 31.87 | Trailing Twelve Months Ending 2022-12 |
Book Value / Share | 163.23 | Trailing Twelve Months Ending 2022-12 |
Price to Book Value | 3.50 | Calculated using Price: 571.00 |
Dividend Yield | 1.05 | Period Ending 2022-03 |
No. of Shares Subscribed | 13.60 Cr. | 135,992,238 Shares |
FaceValue | 1 | |
Company Profile | ||
The company develops, manufactures and commercializes branded pharmaceutical products in select therapeutic areas within the chronic and acute categories of the IPM, such as: cardiovascular; anti-diabetics; vitamins; gastroenterology; and anti-infectives. Its focus has been on developing products in the chronic and acute category which are linked to lifestyle related disorders. |
1 Day |
|
+0.44% |
1 Week |
|
+0.43% |
1 Month |
|
-10.82% |
3 Month |
|
-11.76% |
6 Month |
|
-17.66% |
1 Year |
|
-18.97% |
2 Year |
|
-1.75% |
5 Year |
|
-27.11% |
10 Year |
|
9 years | 2014-03 | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | |
Return on Equity (%) | 50.12 | 40.30 | 47.68 | 56.90 | 41.30 | 28.96 | 24.28 | 24.78 | 23.33 | |
Return on Capital Employed (%) | 68.93 | 49.25 | 54.56 | 62.56 | 35.76 | 26.54 | 25.44 | 27.60 | 25.29 | |
Return on Assets (%) | 32.09 | 28.59 | 36.17 | 43.89 | 27.31 | 20.02 | 20.33 | 22.62 | 21.27 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-09* Rs. Cr. |
Shh. Funds | 177 | 266 | 300 | 567 | 861 | 1,151 | 1,296 | 1,576 | 1,908 | 2,027 | |
Non Curr. Liab. | 18 | 19 | 20 | 12 | 248 | -66 | -80 | -109 | -79 | 183 | |
Curr. Liab. | 71 | 65 | 69 | 129 | 294 | 377 | 220 | 235 | 283 | 360 | |
Minority Int. | 4 | 4 | 3 | 24 | 25 | 18 | 0 | 30 | |||
Equity & Liab. | 270 | 354 | 392 | 732 | 1,428 | 1,481 | 1,437 | 1,703 | 2,113 | 2,600 | |
Non Curr. Assets | 115 | 191 | 169 | 463 | 1,061 | 827 | 902 | 1,167 | 1,402 | 1,984 | |
Curr. Assets | 155 | 163 | 222 | 270 | 367 | 653 | 535 | 536 | 711 | 615 | |
Misc. Exp. not W/O | |||||||||||
Total Assets | 270 | 354 | 392 | 732 | 1,428 | 1,481 | 1,437 | 1,703 | 2,113 | 2,600 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-12 Rs. Cr. TTM |
Net Sales | 509 | 546 | 597 | 750 | 856 | 982 | 1,074 | 1,212 | 1,347 | 1,588 | |
Other Income | 4 | 3 | 3 | 25 | 26 | 32 | 16 | 9 | 26 | 18 | |
Total Income | 513 | 549 | 600 | 775 | 882 | 1,014 | 1,090 | 1,221 | 1,373 | 1,607 | |
Total Expenditure | -410 | -424 | -425 | -480 | -533 | -637 | -706 | -781 | -862 | -1,074 | |
PBIDT | 103 | 125 | 175 | 294 | 349 | 377 | 384 | 439 | 511 | 533 | |
Interest | 0 | 0 | 0 | -1 | -11 | -23 | -2 | -2 | -4 | -19 | |
Depreciation | -5 | -16 | -20 | -23 | -26 | -36 | -50 | -43 | -65 | -100 | |
Taxation | -27 | -20 | -20 | -24 | -17 | -26 | -35 | -39 | -36 | -21 | |
Exceptional Items | |||||||||||
PAT | 71 | 89 | 135 | 247 | 295 | 291 | 297 | 355 | 406 | 393 | |
Minority Interest | 0 | 0 | -1 | 0 | -1 | 0 | 0 | 0 | 4 | ||
Share Associate | |||||||||||
Other Related Items | |||||||||||
Consolidated Net Profit | 71 | 89 | 134 | 247 | 294 | 291 | 297 | 355 | 406 | 397 | |
Adjusted EPS | 5,130 | 6,466 | 9,679 | 18 | 21 | 21 | 22 | 26 | 30 | 29 |
Particulars | 10 years | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. |
Cash Fr. Operatn. | 38 | 90 | 90 | 131 | 200 | 235 | 223 | 271 | 375 | 378 | |
Cash Fr. Inv. | -36 | -83 | -92 | -44 | -184 | -590 | -5 | 123 | -323 | -320 | |
Cash Fr. Finan. | -3 | -2 | 0 | -84 | -24 | 363 | -221 | -335 | -82 | -45 | |
Net Change | -1 | 5 | -2 | 4 | -8 | 8 | -3 | 60 | -30 | 14 | |
Cash & Cash Eqvt | 2 | 7 | 5 | 9 | 2 | 11 | 8 | 67 | 37 | 51 |
Fri, 24 Mar 2023
Announcement under Regulation 30 (LODR)-Updates on Acquisition We refer to our earlier intimations dated 16th March 2023 for acquisition of nine cosmetic dermatology brands from Dr.Reddys Laboratories Ltd. and 21st March 2023 for updation of the deal completion date |
Thu, 23 Mar 2023
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome TRANSCRIPT OF CONFERENCE CALLSCHEDULED IN CONNECTION WITH THE ACQUISITION OF NINE DERMATOLOGY BRANDS FROM DR.REDDYS LABORATORIES LTD |
Tue, 21 Mar 2023
Announcement under Regulation 30 (LODR)-Updates on Acquisition UPDATE ON ACQUISITIONWe refer to the announcement made on 16th March 2023 pertaining to the acquisition of a part of the dermatology portfolio of Dr. Reddys Laboratories Ltd. by way of acquisition of 9 (Nine) trademarks along with their applicable line Extensions.It is hereby notified that based on the comfort derived from the information records documents provided by Dr. Reddys Laboratories Limited so far the completion has been advanced and is now targeted to happen on or about 24th March 2023 instead of the previously targeted date of 31st March 2023. |
Fri, 24 Mar 2023 |
|
|
|
|
|